Arthneeti
All Q2 FY27 results →
LL

Laurus Labs Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Laurus Labs Q2 Results 2026 (FY27): Revenue ₹2,206 Cr, PAT ₹441 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹2,182
Market cap₹1.2L Cr
P/E107.8
Updated29 Oct 2026
Read4 min read

Laurus Labs Ltd Q2 FY27 key numbers

Revenue
Affordable Medicines (AM) 2Q FY27: ₹1,302 crore, +15% Y-o-Y.

As stated in Laurus Labs Ltd's Q2 FY27 investor presentation · published 29 Oct 2026. Reported figures, not investment advice.

Based on Laurus Labs Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

2Q FY27 Revenue: ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). EBITDA for 2Q FY27: ₹762 crore, increased 78% year-on-year (YoY) - EBITDA margin: 34.5%, up 8.5 percentage points YoY - Net Profit (PAT) for 2Q FY27: ₹441 crore, increased 126% YoY - Net Profit

From Laurus Labs Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.

Revenue & Sales Performance

  • 2Q FY27 Revenue: ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q).
  • H1 FY27 Revenue: ₹4,233 crore, up 31% Y-o-Y.
  • Affordable Medicines (AM) 2Q FY27: ₹1,302 crore, +15% Y-o-Y.
  • CDMO 2Q FY27: ₹904 crore, +75% Y-o-Y; small molecules +86% Y-o-Y, bio -38% Y-o-Y.
  • FDF Revenue growth: 31% Y-o-Y in 2Q FY27.
  • ARV Revenue (2Q FY27): ₹735 crore, flat Y-o-Y but +10% Q-o-Q.
  • Volume/Orders: Continued order uptick, volume resilience noted especially in ARV and US portfolio.
  • Outlook:
  • Potential new product launches and integrated CMO engagements.
  • Ramping up product registrations across emerging markets.

2 more points from Laurus Labs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY22-27 CAPEX: ₹5,180+ Cr (16% of Revenue), >85% into diversified portfolio including API, Formulations, Peptides, Fermentation, Gene Therapy, ADCs
  • H1 FY27 CAPEX: ₹864 Cr (20% of Revenue)
  • Planned investment >₹3,000 Cr over FY27 & FY28 for manufacturing network and capability expansion
  • LB-4 Fermentation unit (>400kL) commissioning planned by 3Q FY27
  • KRKA JV FDF site: Phase-I production blocks to open mid-2027, focusing on High Potent and General OSD
  • Peptide manufacturing facility inaugurated ahead of schedule; SPPS capacity >16,000L and expanding
  • Large scale API capacity construction ongoing in Vizag
  • Enzyme fermentation plant: commercial scale manufacturing with future expansion >1.2 million liters

2 more points from Laurus Labs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation reports the following regarding order book, order inflow, or pending orders: - Continued order uptick supports over 13% YoY growth in Affordable Medicines segment. - Healthy outlook driven by potential new launches, integrated CMO engagements, and ramping product registration across Emerging Markets. - KRKA JV FDF site progressing on schedule with Phase-I production blocks opening mid-2027. - Filings update: 92 cumulative DMF filings; 96 cumulative developed market FDF product filings with approvals and pending counts detailed. - CDMO pipeline expanding with high-quality molecules and active projects across multiple technologies. - Scaling enzymatic technology application across clinical and commercial API projects.

2 more points from Laurus Labs Ltd's call on order book

Create a free account to keep reading this call

Laurus Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Laurus Labs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Aarti Pharmalabs Ltd (Q2 FY27)

    19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec

  • Sanofi Consumer Healthcare India Ltd (Q2 FY27)

    Q3 2026 revenue: ₹2,631 million, a 12% year-on-year (Y-o-Y) growth. Key results statement takeaways from Sanofi Consumer Healthcare India Ltd's Q2 FY27 results

  • Sudeep Pharma Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations:** Rs 196.7 crore . Key investor presentation takeaways from Sudeep Pharma Ltd's Q2 FY27 investor presentation — and how it rank

  • Jagsonpal Pharmaceuticals Ltd (Q2 FY27)

    Q2FY27 consolidated revenue: ₹964 Mn, up 29% YoY . Key investor presentation takeaways from Jagsonpal Pharmaceuticals Ltd's Q2 FY27 investor presentation — and

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Laurus Labs Ltd Q2 FY27 results?

2Q FY27 Revenue: ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). EBITDA for 2Q FY27: ₹762 crore, increased 78% year-on-year (YoY) - EBITDA margin: 34.5%, up 8.5 percentage points YoY - Net Profit (PAT) for 2Q FY27: ₹441 crore, increased 126% YoY - Net Profit

What is Laurus Labs Ltd share price analysis?

Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 107.8 with a market cap of ₹117,885 Cr. Investors should review the full earnings analysis for detailed insights.

Is Laurus Labs Ltd planning capital expenditure?

FY22-27 CAPEX: ₹5,180+ Cr (16% of Revenue), >85% into diversified portfolio including API, Formulations, Peptides, Fermentation, Gene Therapy, ADCs - H1 FY27 CAPEX: ₹864 Cr (20% of Revenue) - Plan

Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.